Le LYSA à l’ASH 2022

Les études LYSA présentées au 64ème congrès de l'ASH

La 64ème édition de la réunion annuelle et exposition de l’ASH aura lieu du 10 au 13 décembre 2022 à la Nouvelle-Orléans, en Louisiane.

Cette année, la production scientifique et les études du LYSA seront particulièrement mises à l’honneur lors ce congrès puisque 15 abstracts sous forme de communications orales et posters y seront présentés.

8 communications orales

Samedi 10/12/22

  • 166 : Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma in Transplant-ineligible patients : Primary analysis of ALYCANTE, a Phase 2 LYSA Study

12h45 – Roch Houot


Dimanche 11/12/22

  • 449 : Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, RCHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from LYSA

10h30 – David Sibon

  • 553 : Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry

12h00 – Federico Erbella / Roberta Di Blasi

  • 545 : A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study

13h00 – Herve Ghesquieres


Lundi 12/12/22

  • 722 : Frequent Alterations of Driver Genes in Chromosome X and their Clinical Relevance in Extranodal NK/T-cell Lymphoma

10h45 – Yuta Ito / Lucile Couronné / Amira Marouf

  • 767 : Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A LYSA Study from the DESCAR-T Registry

11h30 – Jean Lemoine

  • 956 : Addition of Brentuximab vedotin to gemcitabine in Relapsed or Refractory T-cell Lymphoma: Final analysis of a LYSA Multicenter, Phase II Study. “The TOTAL Trial”

16h45 – Olivier Tournilhac

  • 959 : Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-cell Lymphoma: Final Analysis of the ORACLE Phase III Study

17h30 – François Lemonnier / Jehan Dupuis

7 posters

Samedi 10/12/22

  • 1596 : The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK Positive ALCL Treated By CHOEP: A Lysa Study

David Sibon – Session 624 – 17H30-19h30

  • 2282 : Evaluation of participation in a prospective real-life multicentric cohort « Real World Data in Lymphoma and Survival in Adults » (REALYSA study) for newly diagnosed lymphoma patients over one year in a hematology department – POSTER

Caroline Le Lan – Session 905 – 17h30-19h30

  • 1652 : Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry

Hedi Bensaber – Session 627 – 17h30-19h30

  • 2226 : CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a LYSA Study Based on the DESCAR-T registry

Gilles Crochet – Session 705 – 17h30-19h30


Dimanche 11/12/22

  • 2878 : Sub-Cutaneous Administration of Rituximab Triggers a Pro-Phagocytic Phenotype of Monocytic Compartment in Low-Tumor Burden Follicular Lymphoma Patients Included in the FLIRT Clinical Trial, a Lysa Study

Mikael Roussel – Session 622 – 18h-20h

  • 2883 : Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study

Anne-Ségolène Cottereau – Session 623 – 18h-20h

  • 2948 : Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final results of 18 patients treated at RP2D of Selinexor in the SELINDA Phase Ib LYSA Study

Marie Maerevoet – Session 626 – 18h-20h